J Biol Chem, Vol. 274, Issue 47, 33469-33473, November 19, 1999
Using a Galactose Library for Exploration of a Novel Hydrophobic
Pocket in the Receptor Binding Site of the Escherichia coli
Heat-labile Enterotoxin*
Wendy E.
Minke
,
Feng
Hong
,
Christophe L. M. J.
Verlinde,
Wim G. J.
Hol§, and
Erkang
Fan¶
From the Department of Biological Structure, the Biomolecular
Structure Center, and the § Howard Hughes Medical Institute,
University of Washington, Seattle, Washington 98195
 |
ABSTRACT |
The binding of the B subunits of
Escherichia coli heat-labile enterotoxin (LT) to epithelial
cells lining the intestines is a critical step for the toxin to invade
the host. This mechanism suggests that molecules which possess high
affinity to the receptor binding site of the toxin would be good leads
for the development of therapeutics against LT. The natural receptor
for LT is the complex ganglioside GM1, which has galactose as its
terminal sugar. A chemical library targeting a novel hydrophobic pocket
in the receptor binding site of LT was constructed based on galactose derivatives and screened for high affinity to the receptor binding site
of LT. This screening identified compounds that have 2-3 orders of
magnitude higher affinity toward the receptor binding site of LT than
the parent compound, galactose. The present findings will pave the way
for developing simple and easily synthesizable molecules, instead of
complex oligosaccharides, as drugs and/or prophylactics against
LT-caused disease.
 |
INTRODUCTION |
Escherichia coli heat-labile enterotoxin
(LT)1 is the causative agent
of traveler's diarrhea and is also responsible for the death of
hundreds of thousands of children each year in developing countries (1,
2). There is currently no prophylaxis and only a very labor-intensive
therapy against diarrhea caused by LT. Therefore, the discovery of
potent inhibitors which can block the function of LT is very important
for the development of effective drugs for the prevention and treatment
of LT-caused diarrhea. The toxin is a heterohexamer and is assembled in
the periplasm of the bacterium with one A subunit which contains its
enzymatic active site and five identical B subunits which are
responsible for target cell recognition. The mechanism of action by LT
can be separated into several stages. After release from the bacterium, LT first binds to epithelial cells lining the intestines through its B
pentameric subunits. The A subunit of LT is then translocated across
the cell membrane. Inside the intestinal cell, the A subunit of the
toxin modifies the
subunit of the trimeric protein Gs so that Gs
loses its GTPase activity and remains
constitutively in its GTP-bound state (3). This in turn causes a
continuous stimulation of adenylate cyclase. The resulting elevated
levels of cyclic AMP in the cell lead to massive loss of fluid and ions from the cell, the characteristic pathology of enterotoxigenic disease.
Based on this mechanism, one approach of developing drugs against LT
would be to create molecules which have high affinity for the receptor
binding site of LT and can therefore block the binding of LT to the
epithelial cells. The natural cell surface receptor for LT is
ganglioside GM1
(Gal-
1,3-GalNAc-
1,4-(NeuAc-
2,3)-Gal-
1,4-Glc-
1,1-ceramide). The oligosaccharide part of GM1 (GM1-OS) is responsible for binding to
LT. Because of the high cost of synthesizing large amounts of complex
oligosaccharide such as GM1-OS, the use of GM1-OS itself or its close
derivatives as drugs against LT would not be economically feasible.
Therefore, the discovery of simple and easily synthesizable small
molecules which can effectively compete with GM1-OS for binding to the
receptor binding site of LT would be of great value.
The three-dimensional structure of LT in its apo state is well known
(4). In addition, the crystal structure of the complex between GM1-OS
and cholera toxin (CT), a closely related toxin with 80% sequence
identity to LT, is also known (5). Structurally, both LT and CT have
essentially identical binding sites for their natural receptor GM1 (5).
Therefore, the two structures (LT and CT) can be used interchangeably
in the design of easily synthesizable small molecules which can inhibit
the receptor binding process of LT. The crystallographically determined
structure of cholera toxin bound to its natural receptor (CT·GM1-OS
(5)) reveals which regions in the toxin can be exploited in drug
design. The two terminal sugars, galactose and sialic acid, make the
most contributions to the binding of GM1 to the toxin, and therefore their binding pockets are the primary targets. Binding of the terminal
galactose group is very specific, because all hydroxyls are involved in
multiple hydrogen bonds with the protein, and substituting this
galactose moiety may be extremely difficult. The sialic acid moiety on
the other hand is less intimately bound by the protein. The sugar ring
of the sialic acid makes hydrophobic interactions with Tyr-12, whereas
the carboxylic acid, the hydroxyl, and the N-acetyl
substituents form hydrogen bonds with the protein backbone. The
glycerol tail is only involved in water-mediated hydrogen bonding.
However, close reexamination of the structure showed that the glycerol
tail is very close to a hydrophobic pocket formed by Ile-58 and Lys-34
of the neighboring B subunit (see Fig. 1A), although no
significant hydrophobic interactions are present. Subsequently, we used
the program GRID with a hydrophobic probe (6) to explore hydrophobic
binding sites in LT. The results suggest that the proposed pocket is
indeed favorable for hydrophobic binding determinants (Fig.
1B) in CT as well as in LT.
The proposed hydrophobic target region formed by Ile-58 and Lys-34 has
never been occupied in any of the other toxin structures complexed to
different galactose derivatives (7-9). Therefore, we wanted to explore
this region by screening ligands composed of galactose, a linker, and a
hydrophobic group for their ability to inhibit toxin binding to GM1.
Galactose was used as an anchor to direct binding to the GM1 pocket,
which is needed to prevent possible unspecific binding of the
hydrophobic group to other hydrophobic regions on the protein. The
linker was necessary to bridge the distance between the galactose C1
atom and the target site for the hydrophobic group, the Ile-58/Lys-34 pocket.
A library of compounds was synthesized to obtain a large and diverse
selection of ligands with a hydrophobic group linked to the galactose
anchor. For this library three different anchors were used, each of
which had a different substituent on C1 of galactose (see Fig. 2). For
the linker, we decided to use polymethylene. It was realized that
conformational freezing of this very flexible linker upon binding would
lead to loss of entropy. However, the rationale was that the
hydrophobic group has to bind rather tightly to compensate for this
entropic loss in order for the ligand to show reasonable inhibition. In
that way we would only select very tight binding hydrophobic groups for
which we can improve the linker in later stages of the project. For the
hydrophobic group, we opted for considerable freedom with respect to
types of ring, which were allowed to have any kind of heteroatoms,
bonding, and substituents. Using a solution phase library synthesis
protocol we recently
developed,2 72 compounds were
synthesized. These library compounds were tested for their ability to
inhibit binding of LT to gangliosides. Two of these compounds appeared
to be the galactose derivatives with the highest affinity for the
receptor binding site observed so far.
 |
EXPERIMENTAL PROCEDURES |
GRID--
The program GRID, Version 16 (6), was used to indicate
energetically favorable binding pockets in the receptor binding site of
LT for a hydrophobic group. To find such favorable binding pockets, a
hydrophobic probe was used with the default parameters to determine the
interaction energies with the protein on a grid with 0.5-Å spacing.
The grid was placed over the 2.2-Å resolution structure of
LT·galactose (11) with the waters and galactose omitted while the
grid covered a volume of 23 × 20 × 20 Å.
Modeling the Linker
Length--
Gal-
NHCO-(CH2)n-Ph,
Gal-
O-(CH2)2-NHCO-(CH2)n-Ph,
and
Gal-
O-(CH2)2-NHCO-(CH2)n-Ph
were built in InsightII (Version 97.0, Biosym/MSI) to represent,
respectively, libraries I, II, and III. The galactose in binding site D
of the LT·galactose structure (11) was used as the starting point
from which the ligands were extended. The dihedrals of these compounds
were adjusted manually to reach the Ile-58/Lys-34 pocket, leaving the
galactose rigid including the C1-N or C1-O dihedral in its optimal
position. For library I, this optimal position has an H1-C1-N1-C7'
dihedral angle of 20°, because in the Cambridge Structural Data Base
(12) five structures of pyranoses which are N-acetylated at
C1 have an average dihedral of 20° ± 15°. For libraries II and
III, the glycosidic torsion prefers the exo-anomeric conformation;
H1-C1-O1-C7' =
60° ± 60° for
D-sugars, and 60° ± 60° for
D-sugars (13). The ligands were energy-minimized using a conjugate
gradient algorithm and the CFF91 forcefield until the r.m.s. derivative
was smaller than 0.001 kcal mol
1 Å
1. The
library compounds were built starting from n = 1, until n was large enough for the phenyl group to be within 4 Å of
either Ile-58 or Lys-34.
ACD3D Data Base Computer Screening--
A two-dimensional
substructure search was conducted in the Available Chemicals Directory,
ACD3D 97.2 (Molecular Design Ltd., San Leandro, CA). The software used
for searching was the program ISIS (Molecular Design Ltd.) (14).
Docking III3J Using SAS--
For flexible docking of III3J to
the rigid target site in pLT the program SAS (25) (Stochastic
Approximation with Smoothing) was used. The protein coordinates used
were prepared as follows: (i) the coordinates of pLT complexed to
galactose (11) were taken from the Protein Data Bank, (ii) galactose
was deleted from the coordinate set, (iii) the positions of the
hydrogens on hetero atoms were determined using the HB2NET option in
the program WHATIF (16), (iv) other hydrogens were added with
InsightII, and (v) charges were assigned using the CFF91 forcefield.
Affinity grids of the protein were calculated using the AUTOGRID
program supplied with the AUTODOCK 2.2 package (17).
The ligand was built in InsightII, subsequently energy-minimized using
a conjugate gradient algorithm and the CFF91 forcefield until the
r.m.s. derivative was smaller than 0.001 kcal mol
1
Å
1, and prepared for flexible docking using the program
add_hydrogens supplied with the SAS package (25).
The default parameters were used for running the docking program SAS.
The ligand was docked 50 times, each time doing 150 cycles of 6000 iterations. After running SAS, the solutions were clustered in groups
with r.m.s. deviations lower than 1.0 Å. The clusters were ranked by
the lowest energy representative of each cluster.
Protein and Chemicals--
Porcine LT holotoxin was expressed
from plasmid pROFIT-LT in E. coli strain MC1061 (18). The
protein was purified using the protocol of Uesaka et al.
(19), except that the clarified cell lysate was subjected to a 30%
ammonium sulfate precipitation in 20 mM Tris-HCl buffer (pH
7.5) prior to affinity chromatography on immobilized
D-galactose. The purity was estimated to be at least 95%
on the basis of silver-stained SDS-polyacrylamide gel electrophoresis
gels. Anti-LT B monoclonal antibody mAb 118-87 was a kind gift from
Dr. T. Hirst (University of Bristol, Bristol, UK). Commercially
obtained assay materials were: IgG horseradish peroxidase conjugate
(Roche Molecular Biochemicals) and GD1b (Matreya, Pleasant Gap, PA).
Commercially obtained acids for library synthesis were:
6-maleimidocaproic acid, 3-cyclohexylpropionic acid, and cyclohexanebutyric acid (Fluka, Milwaukee, WI); 3-phthalimidopropionic acid and 7-phenylheptanoic acid (Lancaster, Windham, NH);
phenytoin-N-butyric acid (Calbiochem, La Jolla, CA);
-N-indolepropionic acid (Pfaltz & Bauer Inc., Waterbury,
CT); and all other acids were from Aldrich.
Synthesis--
Fig. 2A depicts a short schematic of
the synthesis, which uses trialkylphosphine-mediated amide formation
(20). The detailed library synthesis protocol will be published
elsewhere.2 All library compounds screened gave
satisfactory mass spectroscopy results and were judged to be >95%
pure by thin layer chromatography or high performance liquid
chromatography (with a small amount of the corresponding acid starting
material as the contaminant, which was tested to have no adverse effect
on the screening assay). Compounds selected for IC50
measurements were synthesized in larger scale following a similar
protocol as the library synthesis and were all purified by high
performance liquid chromatography before use.
LT GD1b ELISA--
The LT GD1b ELISA was performed as described
by Minke et al. (21). Test samples consisted of 0.2 µg/ml
porcine LT toxin preincubated with the library compound for 2 h at
room temperature. For initial screening, the test samples were diluted
in a 0.1% (w/v) bovine serum albumin/phosphate-buffered saline
solution (saline solution containing 150 mM NaCl and 10 mM potassium phosphate at pH 7.2), and subsequently the
solutions were filtered over a 0.22-µm membrane. For determination of
the IC50 values, the test samples were prepared in 10%
dimethyl sulfoxide (Me2SO), 0.1% bovine serum
albumin/phosphate-buffered saline.
All experiments were carried out in quadruplicate and validated against
a concentration gradient of 0, 0.1, 0.2, and 0.3 µg/ml toxin.
IC50 values were calculated from at least five different concentrations of competitive ligand by nonlinear regression as described previously (22) with the statistical package S-PLUS (Mathsoft, Inc., Cambridge, MA). For the final IC50 values,
the IC50 was determined at least two times in independent
experiments. The reported IC50 of a ligand is the weighted
average (weight = 1/estimated S.D.2) of the
IC50 values from its different determinations.
 |
RESULTS AND DISCUSSION |
The binding pocket of the glycerol tail of GM1 suggested the
presence of a hydrophobic site in LT and CT formed by Ile-58 and
Lys-34, which was supported by the fact that a hydrophobic probe had
very high affinity in this region as determined by the program GRID
(Fig. 1). To explore this binding pocket,
we decided to construct a library from galactose and carboxylate
building blocks (Fig.
2A).2 Manual
docking procedures were used to determine the minimal length of the
methylene linker of the carboxylate building block: a phenyl ring was
positioned in the Ile-58/Lys-34 pocket of LT while the phenyl was
attached to galactose in the galactose binding site through a methylene
linker joined by an amide bond. For sub-library I
(Gal-
NHCO-(CH2)n-Ph) at least three
methylene units were needed to bridge the distance between the
galactose-C1-NH and the hydrophobic pocket. For sub-libraries II and
III
(Gal-O-(CH2)2-NHCO-(CH2)n-Ph,
for sub-library II and
for sub-library III), at least three and
two methylene units were needed, respectively, to reach the Ile-58/Lys-34 pocket. Therefore, it was decided to use carboxylates with two to six methylene units attached to a hydrophobic group as
building blocks for a galactose library to screen for ligands that
inhibit LT binding to GD1b by making use of the hydrophobic pocket.

View larger version (107K):
[in this window]
[in a new window]
|
Fig. 1.
A, GM1 in its binding site in CT as
observed in the 1.25-Å crystal structure (5). The solid
hexagons represent the following sugar moieties of GM1: Gal,
GalNAc, Glc, and Gal. The sialic acid moiety from GM1 is represented by
sticks. B, results from GRID using a hydrophobic
probe on a grid with 0.5-Å spacing over the LT·galactose structure
(11). The green and turquoise balls represent
grid points with GRID energies lower than 0.5 kcal/mol. The
turquoise balls highlight the hydrophobic site formed by
Ile-58 and Lys-34.
|
|

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 2.
Synthesis scheme for the galactose library
(A), starting from 3 different galactose-based anchors (10,
15, 24) and 24 carboxylates. The carboxylates were found by performing
a substructure search in the ACD using a generous search model
(B) which led to the purchase of the 24 acids for library
synthesis with different linker length and different substituents
(C).
|
|
To select appropriate building blocks for library synthesis, the
Available Chemicals Directory was searched for the substructure depicted in Fig. 2B, which yielded 485 carboxylate
containing molecules. These compounds were screened for chemical
properties, and the following substituents were excluded: additional
carboxylates, free alcohols, free amines/imines, free thiols,
aldehydes, borines, seleniums, furans, thienyls, and radicals. In
addition, the following groups were rejected: porphyrins, steroids, and
microperoxidases. Of the remaining 242 compounds we rejected the
doubles, in which we considered methyls and halogens to be identical.
Also, we discarded compounds without a price listing or compounds that
cost more than $100. This led to a group of 58 compounds of which a
subgroup of 33 compounds was selected based on diversity. Of these 33 acids that were ordered, only 24 were actually available and used in the library synthesis. The different linker lengths and different substituents of this final group of acids are depicted in Fig. 2C.
After the synthesis following the protocol developed by
us,2 72 library compounds were constructed with the general
structure as drawn in Fig. 2A and the different substituents
(R-groups) as drawn in Fig. 2C. The library compounds were
tested at 5 mM for inhibition of LT binding to GD1b, and
the results are depicted in Fig. 3. GD1b
was chosen as the appropriate ganglioside because the toxin binds 11 times weaker to GD1b than to GM1 (23), which makes it possible to
screen for lower affinity inhibitors. We would like to point out that a
few compounds were tested at a concentration below 5 mM as
a result of a low yield in the synthesis or because of solubility
problems; these compounds are marked with an asterisk in
Fig. 3. The following compounds showed more than 50% inhibition and
were subsequently tested at 0.5 mM: I2J (I2J denotes the
sub-library I compound with a linker of two methylene units and
substituent 2J), I3J, I4C, II2B, II2C, II2F, II2G, II3J, II4B, II4C,
and II6A. At 0.5 mM only galactose library compounds II3J
and II6A showed significant inhibition in the LT ELISA, respectively, 100% and 60%. Subsequently these compounds were synthesized at larger
scale to confirm their inhibitory power and to determine the
IC50. Unfortunately, the results with compound II6A from
the larger scale do not confirm with the earlier, screening results: the IC50 is only 3.2 ± 0.1 mM. The better
result obtained during the initial screening may have been because of
impurities in the smaller scale library synthesis. However, compound
II3J is indeed an extremely good inhibitor with an IC50 of
0.23 ± 0.04 mM (Fig. 4A), which means that the
affinity is 300-fold higher than that of galactose (21). Because II3J
is such a good inhibitor and compound III3J was only tested at an
unknown and very low concentration, we also decided to resynthesize
library compound III3J at a larger scale and test it in an appropriate
solvent. The presence of 10% Me2SO in the II3J sample
solutions did not have any effect on the IC50 of II3J (Fig.
4A), and in addition, III3J dissolved completely in the
presence of 10% Me2SO. Therefore, the IC50 of
III3J was determined in the presence of 10% Me2SO and
turns out to be 40 ± 2 µM (Fig. 4B). The
IC50 of III3J is even 5-fold better than its
-isomer in
library II or in other words it is 1500-fold better than galactose.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 3.
Inhibition of toxin binding to GD1b-coated
microtiter plates by the galactose library compounds. Inhibition
was determined using the LT GD1b ELISA as described under
"Experimental Procedures." The LT concentration was 0.2 µg/ml.
The ligand concentration was 5 mM unless the result is
marked by a star, which refers to a lower and unknown ligand
concentration because of problems during synthesis or dissolution of
the library compound. The arrows indicate the compounds that
were tested further in Fig. 4.
|
|

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 4.
Inhibition of toxin binding to GD1b-coated
microtiter plates by II3J (A) and III3J
(B). Inhibition was determined using the LT GD1b
ELISA as described under "Experimental Procedures." The LT
concentration was 0.2 µg/ml. For II3J, the experiment was performed
in the absence and presence of 10% Me2SO
(DMSO). For III3J, the experiment was only done in the
presence of 10% Me2SO.
|
|
Besides identifying several tight binding inhibitors of LT binding to
GD1b, another motivation for designing, synthesizing and screening a
galactose library was to analyze characteristics of this library for
the design of future inhibitors. First of all, the effect of the linker
length should be discussed. As was predicted, a linker of two methylene
units is too short for libraries I and III (compounds I2J and III2J
being exceptions, probably because of the presence of a second phenyl
group). However, for the compounds with longer linkers in libraries I
and III and for library II, there is not a clear correlation between
linker length and inhibition of LT binding to GD1b. Second, library II
distinctly contains better inhibitors (Fig. 3), although the best
compound is from library III. This confirms our earlier findings that
anomers of galactose derivatives in general are better inhibitors than their
anomers (21). To conclude, library II contains relatively the most potent inhibitors, and even compounds with the
smallest linker in this library perform well in the ELISA. Therefore,
it is probably wise to expand this library in the future and also
include compounds in library II with only one methylene group as the linker.
Of course our immediate goal is to follow up the hits of this
successful library screen. To design the next round of inhibitors based
on the very potent inhibitor III3J, we need to know its exact binding
mode. Initially, we tried to expedite the design process by predicting
the binding mode of III3J in LT using the docking program SAS. However,
as shown in Fig. 5, no single binding mode was preferred. Instead, of the 50 solutions suggested by the
program, only 7 were within 1 Å of another solution. Therefore, we are
in the process of crystallizing the LT·III3J complex to obtain a
better model for the binding mode of III3J in LT.

View larger version (68K):
[in this window]
[in a new window]
|
Fig. 5.
Several binding modes of III3J in LT as
suggested by the docking program SAS (25). The second solution had
a score of 84.28 kcal/mol with two members in its cluster. The fifth
solution had a score of 79.08 kcal/mol with three members in its
cluster. The third solution had a score of 71.86 kcal/mol with one
member in its cluster. These solutions were selected to demonstrate the
diversity in the proposed binding modes. For completeness, the first
ranked solution had a score of 89.92 cal/mol and had two members in
its cluster. The turquoise spheres are identical to the ones
in Fig. 1B and represent the hydrophobic binding site.
|
|
 |
ACKNOWLEDGEMENTS |
We thank Dr. David Diller for early release
of the program SAS and Dr. Peter Goodford for providing GRID. And we
are very grateful to Dr. Tim Hirst for providing us with anti-LTB.
 |
FOOTNOTES |
*
This work was supported through a grant by the School of
Medicine, Department of Biological Structure, University of Washington (to E. F.) and by the National Institutes of Health Grants GM54618 (to
C. V.) and AI34501 (to W. H.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Both authors contributed equally to the work presented in this paper.
¶
To whom correspondence should be addressed: Dept. of
Biological Structure, University of Washington, Box 357742, Seattle, WA
98195. Tel.: 206-685-7048; Fax: 206-685-7002; E-mail:
erkang@u.washington.edu.
2
F. Hong and E. Fan, submitted for publication.
 |
ABBREVIATIONS |
The abbreviations used are:
LT, heat-labile
enterotoxin;
ACD, Available Chemicals Directory;
CT, cholera toxin;
Gal, galactose;
Glc, glucose;
r.m.s., root mean square;
SAS, Stochastic
Approximation with Smoothing;
GM1-OS, oligosaccharide part of GM1;
ELISA, enzyme-linked immunosorbent assay.
 |
REFERENCES |
| 1.
|
Wanke, C. A.,
Lima, A. A.,
and Guerrant, R. L.
(1987)
Baillieres Clin. Gastroenterol.
1,
335-359[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Holmgren, J.,
and Svennerholm, A. M.
(1992)
Gastroenterol. Clin. N. Am.
21,
283-302[Medline]
[Order article via Infotrieve]
|
| 3.
|
Spangler, B. D.
(1992)
Microbiol. Rev.
56,
622-647[Abstract/Free Full Text]
|
| 4.
|
Sixma, T. K.,
Pronk, S. E.,
Kalk, K. H.,
Wartna, E. S.,
van Zanten, B. A.,
Witholt, B.,
and Hol, W. G. J.
(1991)
Nature
351,
371-377[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Merritt, E. A.,
Kuhn, P.,
Sarfaty, S.,
Erbe, J. L.,
Holmes, R. K.,
and Hol, W. G. J.
(1998)
J. Mol. Biol.
282,
1043-1059[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Goodford, P. J.
(1985)
J. Med. Chem.
28,
849-857[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Sixma, T. K.,
Pronk, S. E.,
Kalk, K. H.,
Van Zanten, B. A.,
Berghuis, A. M.,
and Hol, W. G. J.
(1992)
Nature
355,
561-564[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Van den Akker, F.,
Feil, I. K.,
Roach, C.,
Platas, A. A.,
Merritt, E. A.,
and Hol, W. G. J.
(1997)
Protein Sci.
6,
2644-2649[Abstract]
|
| 9.
|
Merritt, E. A.,
Sarfaty, S.,
Feil, I. K.,
and Hol, W. G. J.
(1997)
Structure
5,
1485-1499[Medline]
[Order article via Infotrieve]
|
| 10.
|
Chernyak, A. Y.,
Sharma, G. V. M.,
Kononov, L. O.,
Krishna, P. R.,
Levinsky, A. B.,
Kochetkov, N. K.,
and Rama Rao, A. V.
(1992)
Carbohydr. Res.
223,
303-309[CrossRef]
|
| 11.
|
Merritt, E. A.,
Sixma, T. K.,
Kalk, K. H.,
Van Zanten, B. A.,
and Hol, W. G. J.
(1994)
Mol. Microbiol.
13,
745-753[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Allen, F.,
and Kennard, O.
(1993)
Chem. Des. Automa. News
8,
1 and 31-37
|
| 13.
|
Tvaroska, I.,
and Bleha, T.
(1989)
Adv. Carb. Chem. Biochem.
47,
45-123
|
| 14.
|
Moock, T. E.,
Henry, D. R.,
Ozkabak, A. G.,
and Alamgir, M.
(1994)
J. Chem. Info. Comput. Sci.
34,
184-189
|
| 15.
|
Apparu, M.,
Blanc-Muesser, M.,
Defaye, J.,
and Driguez, H.
(1981)
Can. J. Chem.
59,
314-320[CrossRef]
|
| 16.
|
Hooft, R. W.,
Sander, C.,
and Vriend, G.
(1996)
Proteins
26,
363-376[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Goodsell, D. S.,
and Olson, A. J.
(1990)
Proteins
8,
195-202[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Feil, I. K.,
Reddy, R.,
de Haan, L.,
Merritt, E. A.,
Van den Akker, F.,
Storm, D. R.,
and Hol, W. G. J.
(1996)
Mol. Microbiol.
20,
823-832[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Uesaka, Y.,
Otsuka, Y.,
Lin, Z.,
Yamasaki, S.,
Yamaoka, J.,
Kurazono, H.,
and Takeda, Y.
(1994)
Microbial. Pathogen.
16,
71-76
|
| 20.
| Inazu, T., and Kobayashi, K. (1993) Synlett 869-870
|
| 21.
|
Minke, W. E.,
Roach, C.,
Hol, W. G. J.,
and Verlinde, C. L. M. J.
(1999)
Biochemistry
38,
5684-5692[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Bowen, W. P.,
and Jerman, J. C.
(1995)
Trends Pharmacol. Sci.
16,
413-417[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Sugii, S.,
and Tsuji, T.
(1989)
Can. J. Microbiol.
35,
670-673[Medline]
[Order article via Infotrieve]
|
| 24.
|
Susaki, H.,
Suzuki, K.,
Ikeda, M.,
Yamada, H.,
and Watanabe, H.
(1994)
Chem. Pharm. Bull.
42,
2090-2096
|
| 25.
| Diller, D. J., and Verlinde, C. L. M. J. (1999) J. Comput.
Chem., in press
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.